IDiyas

For the Inventor, By the Inventor

Salem, CT, United States of America

Daniel Wei-Shung Kung

USPTO Granted Patents = 11 

 

 

Average Co-Inventor Count = 5.6

ph-index = 3

Forward Citations = 35(Granted Patents)


Company Filing History:

goldMedal11 out of 4,455 
 
Pfizer Corporation
 patents

Years Active: 2012-2025

Loading Chart...
Loading Chart...
Loading Chart...
11 patents (USPTO):
1. 12312344 - N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors (2025-05-27),
2. 11708360 - N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors (2023-07-25),
3. 10975065 - N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors (2021-04-13),
4. 9873673 - 2-thiopyrimidinones (2018-01-23),
5. 9440949 - Diacylglycerol acyltransferase 2 inhibitors (2016-09-13),
6. 9399626 - 2-thiopyrimidinones (2016-07-26),
7. 9394285 - Indole and indazole compounds that activate AMPK (2016-07-19),
8. 9139587 - N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors (2015-09-22),
9. 8802690 - N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors (2014-08-12),
10. 8507681 - N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors (2013-08-13),
11. 8288405 - N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors (2012-10-16),

Title: The Innovative Contributions of Daniel Wei-Shung Kung

Introduction

Daniel Wei-Shung Kung is a prominent inventor based in Salem, CT (US). He holds a total of 11 patents, showcasing his significant contributions to the field of pharmaceutical sciences. His work primarily focuses on developing compounds that have therapeutic applications.

Latest Patents

Among his latest patents is the invention of N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides, which are useful as CCR6 inhibitors. This invention relates to compounds that inhibit CC chemokine receptor 6 (CCR6), along with pharmaceutical compositions containing these compounds. These innovations are aimed at treating or preventing diseases, conditions, or disorders that can be ameliorated by the inhibition of CCR6.

Career Highlights

Daniel has had a notable career, working with leading pharmaceutical companies such as Pfizer Corporation and Pfizer Products Inc. His experience in these organizations has allowed him to contribute to significant advancements in drug development and therapeutic solutions.

Collaborations

Throughout his career, Daniel has collaborated with esteemed colleagues, including Scott William Bagley and David Andrew Griffith. These collaborations have further enriched his work and expanded the impact of his inventions.

Conclusion

Daniel Wei-Shung Kung's innovative contributions to pharmaceutical sciences, particularly in the development of CCR6 inhibitors, highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…